优泌乐25治疗新诊断2型糖尿病的疗效观察(2)
第1页 |
参见附件。
参考文献
[1]Wenying Yang,Juming Lu, Jianping Wen,etal.Prevalence of diabetes among Men and Women in China [J].N Engl J Med,2010.362:1090-1101.
[2] 廖二元.内分泌学[M].第2版.北京:人民卫生出版社,2007:1354~14l8.
[3]Radziuk JR, Bradley B,Welsh L, et al1Neutral p rotamine lispro:Activityprofile of s.c.administration with and without admixture of soluble lisp ro.Diabetologia, 1996, 39 ( Supp11) : A224.
[4] JansseMnM J, CasteleijnS,DevilleW, et al.Nighttime insulin kinetics and glucemic control in type 1 diabetes patients following administration of an intermediate - acting lisp ro preparation.Diabetes Care,1997, 20: 1870 - 1873.
[5] Roach P, Yue L Arora V, The HumalogMix25 Study Group. Imp roved postp randial glycemic control during treatmentwith HumalogMix25, a novelprotaminebased insulin lisp ro fotmulation.Diabetes Care, 1999,22: 1258 - 1261.
[6] Roach P, Trautmann M, Arora V, et al. Imp roved postp randiabl lood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro - protamine formulations, lnsulin Lispro Mix25 and lnsulin Lisp roMix50.Clin Ther, 1999, 21: 523 - 534.
您现在查看是摘要介绍页,详见PDF附件(1815kb)。